KOBO Biotech

KOBO Biotech EBIT per Share

The EBIT per Share of KOBO Biotech (531541.BO) as of Oct 23, 2026 is -2.08 INR. In the previous year, EBIT per Share was -2.34 INR — a change of -11.13% (higher).

EBIT per Share

-2.08INR

YoY

-11.13%

Last updated:

EBIT per Share of KOBO Biotech is 2024 -2.08 INR. EBIT per Share of KOBO Biotech was 2023 -2.34 INR. It decreases by -11.13% higher compared to the previous year.

The KOBO Biotech EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2017
-4.52 INR
Jan 1, 2018
-4.00 INR
Jan 1, 2019
-3.84 INR
Jan 1, 2020
-3.57 INR
Jan 1, 2021
-3.29 INR
Jan 1, 2022
-6.35 INR
Jan 1, 2023
-2.34 INR
Jan 1, 2024
-2.08 INR
The KOBO Biotech EBIT per Share history
YEAREBIT per ShareYoY
-2.08INR-11.13%
-2.34INR-63.20%
-6.35INR+92.73%
-3.29INR-7.66%
-3.57INR-7.11%
-3.84INR-3.89%
-4.00INR-11.66%
-4.52INR+327.09%
-1.06INR-86.18%
-7.66INR+63.57%
-4.68INR-132.03%
14.63INR-9.49%
16.16INR+57.40%
10.27INR+13.40%
9.05INR+33.31%
6.79INR+1,328.04%
0.48INR-105.94%
-8.01INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

KOBO Biotech Stock analysis

What does KOBO Biotech do? Kobo Biotech Ltd. focuses on manufacturing active pharmaceutical ingredients (APIs)/bulk drugs. The company operates within the pharmaceuticals sector, producing bulk drugs for the industry. Its primary market segment consists of pharmaceutical manufacturers seeking reliable API suppliers. The firm's Solapur site in India is currently inactive, with no operational activities ongoing there. The company's revenue streams derive from the sale of manufactured APIs and bulk drugs to pharmaceutical companies. These products are essential components in the production of finished pharmaceutical formulations. Kobo Biotech Ltd. serves as a key supplier within the pharmaceutical supply chain, providing critical raw materials to its clients. The business model centers on bulk drug manufacturing, with the company acting as a supplier to other pharmaceutical firms. There are no additional product lines or services mentioned beyond API and bulk drug production. The firm's focus remains strictly on the manufacturing of active pharmaceutical ingredients and bulk drugs for the pharmaceutical industry. KOBO Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about KOBO Biotech stock

EBIT per Share of KOBO Biotech is -2.08 INR in 2024.

EBIT per Share of KOBO Biotech changed from -2.34 INR to -2.08 INR, representing a -11.13% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share KOBO Biotech since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — KOBO Biotech

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — KOBO Biotech